This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

VATS Major Lung Resection for Chinese Early-stage Non-small Cell Lung Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2015 by Jun Wang, Peking University People's Hospital.
Recruitment status was:  Recruiting
Sponsor:
Information provided by (Responsible Party):
Jun Wang, Peking University People's Hospital
ClinicalTrials.gov Identifier:
NCT01707888
First received: October 13, 2012
Last updated: January 24, 2015
Last verified: January 2015
  Purpose
Surgery may be the best treatment choice for early stage non-small cell lung cancer. And VATS major lung resection have been preferred as a standard radical procedure for early stage non-small cell lung cancer (NSCLC).This study aim to investigate the outcome of VATS major lung resection for lung cancer as a real-world study in china.

Condition Intervention Phase
Non-small Cell Lung Cancer Procedure: Thoracoscopy/VATS Phase 3

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration: 3 Years
Official Title: VATS Major Lung Resection for Chinese Early-stage Non-small Cell Lung cancer-a Registry Study

Resource links provided by NLM:


Further study details as provided by Jun Wang, Peking University People's Hospital:

Primary Outcome Measures:
  • morbidity and mortility rate [ Time Frame: 3 moths ]
    perioperative complications and death rates of the group


Secondary Outcome Measures:
  • Disease-free survival [ Time Frame: 3y ]
    To evaluate Disease Free Survival (DFS) of the group.

  • Rate of loco-regional and systemic recurrence [ Time Frame: 3y ]
    To evaluate the rate of loco-regional and systemic recurrence of the group.

  • Pulmonary function [ Time Frame: 6 months after surgery ]
    to evaluate the pulmonary function as measured by expiratory flow rate of the group 6 months postoperatively.

  • Postoperative hospital stay. [ Time Frame: 3 months postoperatively ]
    to evaluate the postoperative hospital stay of the group.

  • Postoperative drainage duration [ Time Frame: 3 months postoperatively ]
    to evaluate the postoperative drainage duration of the group.

  • overall survival [ Time Frame: 3 months postoperatively ]
    to evaluate the overall survival rate of the group.

  • converted rate [ Time Frame: 3 months ]
    the rate of converted thoracotomy


Estimated Enrollment: 500
Study Start Date: September 2014
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
major lung resection
Patients undergo major lung resection by thoracoscopy/VATS.
Procedure: Thoracoscopy/VATS
Patients undergo major lung resection by thoracoscopic surgery or video assisted thoracoscopic surgery.
Other Name: Minimal invasive surgery

Detailed Description:
Surgery may be the best treatment choice for early stage non-small cell lung cancer. And VATS major lung resection have been preferred as a standard radical procedure for early stage non-small cell lung cancer (NSCLC).This study aim to investigate the outcome of VATS major lung resection for lung cancer as a real-world study in china.This is a multicenter, prospective study, aimed To evaluate the short-term and long- term outcome of VATS major lung resection for early stage lung cancer. Patients will be followed up every 3 months for 3 years.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
clinical early stage(I/II) lung cancer
Criteria

Inclusion Criteria:

Preoperative criteria:

i) non-small cell lung cancer is suspected, ii) clinical stage I/II (3) Intraoperative criteria: i) Histologically confirmed NSCLC, ii) resected by VATS or converted open lobectomy,sleeve lobectomy or pneumonectomy and nodal dissection/sampling.

(4) No prior ipsilateral thoracotomy (prior diagnostic thoracoscopy is allowed).

(5) No prior chemotherapy or radiation therapy for any malignant diseases. (6) Expected postoperative FEV1.0>=800 mL and PaO2>=65 torr. (7) Performance status of 0 or 1. (8) Sufficient organ functions. (9) Written informed consent.

Exclusion Criteria:

  1. Active bacterial or fungous infection.
  2. Simultaneous or metachronous (within the past 5 years) double cancers.
  3. Women during pregnancy or breast-feeding.
  4. Interstitial pneumonitis, pulmonary fibrosis, or severe pulmonary emphysema.
  5. Psychosis.
  6. Systemic steroids medication.
  7. Uncontrollable diabetes mellitus.
  8. Uncontrollable hypertension.
  9. History of severe heart disease, heart failure, myocardial infarction within the past 6 months or attack of angina pectoris within the past 6 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01707888

Contacts
Contact: Jun Wang, MD 88324078 Jwangmd@yahoo.com

Locations
China, Beijing
Beijing Anzhen Hospital Not yet recruiting
Beijing, Beijing, China, 100044
Contact: Songlei Ou         
Beijing Cancer Hospital Not yet recruiting
Beijing, Beijing, China, 100044
Contact: Keneng Chen         
Beijing Chao-Yang Hospital Not yet recruiting
Beijing, Beijing, China, 100044
Contact: Hui Li         
Beijing Haidian Hospital Recruiting
Beijing, Beijing, China, 100044
Contact: Yuqing Huang         
China
Beijing Friendship Hospital Not yet recruiting
Beijing, China
Contact: Zhi Gao         
Peking university people's hospital Recruiting
Beijing, China
Contact: Jun Wang, MD         
Sponsors and Collaborators
Peking University People's Hospital
Investigators
Study Chair: Jun Wang, MD Peking University People's Hospital
Study Director: Fan Yang, MD Peking University People's Hospital
Study Director: Zhao Xi Sui, MD Peking University People's Hospital
  More Information

Responsible Party: Jun Wang, Principal Investigator, Clinical Professor, Peking University People's Hospital
ClinicalTrials.gov Identifier: NCT01707888     History of Changes
Other Study ID Numbers: PEKUPH1201
Study First Received: October 13, 2012
Last Updated: January 24, 2015

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms

ClinicalTrials.gov processed this record on June 28, 2017